Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
dose interruption
Description:
A temporary pause in administering a medication or treatment, often used to manage toxicity or other clinical concerns.
Related topics:
Chronic Myeloid Leukemia Treatments (9%),
Advanced Breast Cancer Therapies (7%),
Chronic Lymphocytic Leukemia Research (7%)
OpenAlex ID:
keywords/dose-interruption
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
2013
·
Timothy P. Hughes
, Giuseppe Saglio
, et al.
·
Blood
·
268
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
2009
·
Gianantonio Rosti
, Francesca Palandri
, et al.
·
Blood
·
222
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
2020
·
D Baker
, C A K Roberts
, et al.
·
Clinical & Experimental Immunology
·
197
PDF
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
2018
·
Marc Thill
, Marcus Schmidt
·
Therapeutic Advances in Medical Oncology
·
190
PDF
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
2013
·
Hagop M. Kantarjian
, Jorge E. Cortes
, et al.
·
Blood
·
158
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®)
2004
·
Yvonne Lassere
, Paulo Hoff
·
European Journal of Oncology Nursing
·
148
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review
2022
·
Ziad Abuhelwa
, Abdurahman Alloghbi
, et al.
·
Drugs
·
145
PDF
Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).
2011
·
A. Cheng
, Y. Kang
, et al.
·
Journal of Clinical Oncology
·
121
Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer
2018
·
Makoto Tahara
, Marcia S. Brose
, et al.
·
European Journal of Cancer
·
115
PDF
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis
2020
·
Alessandro Rizzo
, Margherita Nannini
, et al.
·
Therapeutic Advances in Medical Oncology
·
109
PDF
Everolimus: side effect profile and management of toxicities in breast cancer
2013
·
Elisavet Paplomata
, Amelia Zelnak
, et al.
·
Breast Cancer Research and Treatment
·
101
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
2019
·
Lindsey E. Roeker
, Christopher P. Fox
, et al.
·
Clinical Cancer Research
·
92
Pleural effusions due to dasatinib
2010
·
Anupama G Brixey
, Richard W Light
·
Current Opinion in Pulmonary Medicine
·
83
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
2018
·
Jorge E. Cortes
, Jane F. Apperley
, et al.
·
Journal of Hematology & Oncology
·
82
PDF
Oxaliplatin-Induced Neuropathy in Colorectal Cancer
2011
·
Andrew Weickhardt
, Keith Wells
, et al.
·
Journal of Oncology
·
81
PDF
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
2008
·
Aristoteles Giagounidis
, Pierre Fenaux
, et al.
·
Annals of Hematology
·
80
PDF
Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma--Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off
2014
·
T. Kondo
, T. Takagi
, et al.
·
Japanese Journal of Clinical Oncology
·
79
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
2009
·
David Masiello
, Gerry Gorospe
, et al.
·
Journal of Hematology & Oncology
·
69
PDF
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
2004
·
Werner Scheithauer
, Joanne Blum
·
PubMed
·
69
Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults
2023
·
Michael Weller
, Emilie Le Rhun
, et al.
·
Neuro-Oncology
·
68
PDF
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
2015
·
Naval Daver
, Jorge Cortes
, et al.
·
Haematologica
·
66
PDF
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805
2015
·
Naomi B. Haas
, Judith Manola
, et al.
·
Clinical Cancer Research
·
66
Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors
2023
·
Paolo Bossi
, Paolo A. Ascierto
, et al.
·
Critical Reviews in Oncology/Hematology
·
60
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
2014
·
Brian I. Rini
, David I. Quinn
, et al.
·
Targeted Oncology
·
60
PDF
Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients
2015
·
Thomas Powles
, Sergio Bracarda
, et al.
·
European Journal of Cancer
·
58
Show more works
View as search
Works count:
329
Citation count:
4,969
Year
Topic
Type